Leading researchers from academia, government, private institutions, pharmaceutical and biotechnology companies, contract research companies and other stakeholders will gather November 15-18 at the CNS Summit 2012 to collaborate on research issues.
The CNS Summit will launch with the Innovation Satellite demonstrating the impact of technology and cutting edge research on the future of CNS drug development. Speakers will represent the National Institute of Mental Health, Microsoft, Qualcomm Life, 23andMe, McKinsey and Company and other leading entities shaping the future.
The main CNS Summit will discuss issues such as precompetitive collaboration, patient-centric and data-driven drug development and “thinking differently.” The Innovation Showcases will feature novel technologies with direct application to clinical trials.
The Co-chair of the Scientific Program Committee, Dr. Judith Dunn, from F. Hoffmann- La Roche, commented, “The guiding principles of the CNS Summit are Collaboration, Innovation, Acceleration and Technology. The agenda developed by the Scientific Program Committee this year delivers on all of those themes and is focused on enhancing the abilities of clinical researchers at the CNS Summit to impact the future of drug development.”